On the upside
FBR Capital initiated coverage of Wabash National (NYSE: WNC) with an Outperform rating.
Analysts expect Qualcomm (Nasdaq: QCOM) to report higher third quarter earnings next week.
On the downside
Acadia Pharmaceuticals (Nasdaq: ACAD) halted development of its schizophrenia drug AM-831 after it failed a Phase I clinical trial.
Shares of Supervalu (NYSE: SVU) continued falling after reporting sharply lower earnings yesterday.
Lexmark (Nasdaq: LXK) cut its guidance for the second quarter due to weaker than expected demand.
In the broad market, advancing issues outpaced decliners by a margin of more than 9 to 2 on the NYSE and by more than 5 to 2 on Nasdaq. The Russell 2000 which tracks small cap stocks surged 11 points to 800.